Cutaneous T-Cell Lymphoma (CTCL) (DBCOND0071861)

Identifiers

Synonyms
Cutaneous T Cell Lymphoma (CTCL) / Cutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma / Cutaneous T Cell Lymphoma / Cutaneous T-Cell Lymphomas / CTCL / Primary cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma (morphologic abnormality) / Primary cutaneous T-cell lymphoma (disorder) / Lymphoma, T-Cell, Cutaneous

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Cladribine
A purine antimetabolite used to treat Multiple Sclerosis (MS) and hairy cell leukemia.
Gemcitabine
A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.
Interferon alfa-2a
A form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
Methoxsalen
A furocoumarin used to treat psoriasis and vitiligo.
Pralatrexate
An antineoplastic agent used for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Romidepsin
A histone deacetylase (HDAC) inhibitor used to treat cutaneous T-cell lymphoma.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT02689453
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)treatment1completed
NCT02542124
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)treatment2unknown_status
NCT01087333
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentNo drug interventionsNot AvailableNot Availablerecruiting
NCT01579318
Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphomatreatment2terminated
NCT06470451
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLtreatment3not_yet_recruiting
NCT05956041
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomastreatment2recruiting
NCT05680558
Photopheresis in Early-stage Mycosis Fungoidestreatment2recruiting
NCT03292406
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)No drug interventionstreatment2completed
NCT00221039
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2Atreatment4completed
NCT03493451
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasmstreatment2completed
NCT01486277
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphomatreatment2completed
NCT02593045
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)treatment1completed
NCT02811783
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCLtreatment3terminated
NCT03302728
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphomatreatment1completed
NCT00099593
Immunization Against Tumor Cells in Sezary SyndromeNo drug interventionstreatment2completed
NCT02676778
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphomatreatment2completed
NCT05827107
Skin Barrier and Microbiome of CTCL PatientsNo drug interventionsNot AvailableNot Availableenrolling_by_invitation
NCT02567656
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell LymphomaNo drug interventionstreatment1completed
NCT00969085
Trial of Curcumin in Cutaneous T-cell Lymphoma Patientstreatment2withdrawn
NCT00254332
Effect of Denileukin Diftitox on Immune System in CTCL PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT03116659
CTCL Directed Therapytreatment0unknown_status
NCT06285370
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapytreatment4recruiting
NCT01578499
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)treatment3completed
NCT02061449
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphomatreatment1terminated
NCT00001249
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tactreatment1completed
NCT02881749
Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoidestreatment2unknown_status
NCT02181218
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomastreatment1completed
NCT03601819
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorderstreatment1terminated
NCT01134341
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomatreatment1completed
NCT00779896
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Studytreatment1 / 2unknown_status
NCT05138458
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCLNo drug interventionstreatment1 / 2suspended
NCT02836886
VircapSeq Virus Detection in Sézary SyndromeNo drug interventionsNot AvailableNot Availablecompleted
NCT06037239
Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Studytreatment1 / 2recruiting
NCT00341939
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics DataNo drug interventionsNot AvailableNot Availablecompleted
NCT03646422
AEDV Registry of Primary Cutaneous LymphomaNo drug interventionsNot AvailableNot Availablerecruiting
NCT03775525
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancertreatment1active_not_recruiting
NCT04234048
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphomatreatment1recruiting
NCT06113081
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell LymphomaNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT06436677
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell LymphomaNo drug interventionsNot AvailableNot Availablerecruiting
NCT05414500
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoidestreatment1recruiting
NCT04955340
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostattreatment1completed
NCT05205902
TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis FungoidesNo drug interventionsother3not_yet_recruiting
NCT05872854
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Lighttreatment2recruiting
NCT05728879
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray SolutionNo drug interventionstreatment0not_yet_recruiting
NCT04045470
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell LymphomaNo drug interventionsdiagnosticNot Availablerecruiting
NCT03235869
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphomatreatment0withdrawn
NCT02539472
Early Diagnosis of Mycosis FungoidesNo drug interventionsdiagnosticNot Availableunknown_status
NCT02192021
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)treatment1completed
NCT01676831
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)treatment1 / 2completed
NCT01663571
STAT3 in T Cells: At The Crossroads of Inflammation and CancerNo drug interventionsNot AvailableNot Availableterminated
NCT01460914
Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis TreatmentNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT01132989
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphomatreatment2unknown_status
NCT00007345
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphomatreatment2completed
NCT03380026
Mechlorethamine Induced Contact Dermatitis Avoidance Studysupportive_care2completed
NCT01433731
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)treatment1completed
NCT04998331
A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotinNo drug interventionsNot AvailableNot Availablecompleted
NCT00490776
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)treatment2terminated
NCT06382844
Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCLNo drug interventionsNot AvailableNot Availablerecruiting
NCT03563040
Study of Photopheresis in the Treatment of Erythrodermic MF and SStreatment2withdrawn
NCT01445340
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphomatreatment1terminated
NCT00419367
Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)Not AvailableNot Availableno_longer_available
NCT05333367
MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal PhotochemotherapyNo drug interventionsbasic_scienceNot Availableunknown_status
NCT05296304
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoidestreatment1recruiting
NCT06120504
A Safety Study of SGN-35T in Adults With Advanced CancersNo drug interventionstreatment1recruiting
NCT00177268
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchNo drug interventionsNot AvailableNot Availablerecruiting
NCT01187446
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoidestreatment1 / 2terminated
NCT02448381
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)treatment3completed
NCT00425555
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphomatreatment2completed
NCT01196208
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001Not AvailableNot Availableno_longer_available
NCT02643303
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancerstreatment1 / 2completed
NCT00177190
In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)No drug interventionsNot AvailableNot Availablecompleted
NCT01637090
Everolimus in Treating Cutaneous T-cell Lymphomatreatment2terminated
NCT03789864
Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis FungoidesNo drug interventionsdevice_feasibilityNot Availableterminated
NCT03902184
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphomatreatment2active_not_recruiting
NCT00274651
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomastreatment2terminated
NCT02840747
Tissue Repository: CTCL Collection ProtocolNo drug interventionsNot AvailableNot Availablerecruiting
NCT05137847
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)Not AvailableNot Availablecompleted
NCT02296398
Long-term Use of Romidepsin in Patients With CTCLNot AvailableNot Availablecompleted
NCT00211198
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)treatment4completed
NCT01728805
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLtreatment3completed
NCT02512497
Romidepsin Maintenance After Allogeneic Stem Cell Transplantationtreatment1unknown_status
NCT00412997
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphomatreatment1completed
NCT00051597
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignanciestreatment1 / 2completed
NCT01556828
Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid SequencingNo drug interventionsNot AvailableNot Availableterminated
NCT00896493
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphomatreatment2completed
NCT00071071
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.treatment2completed
NCT02341209
Doxycycline for the Treatment of Cutaneous T-Cell Lymphomatreatment2terminated
NCT00091559
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)treatment2completed
NCT02323659
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomastreatment4terminated
NCT00050999
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patientstreatment4completed
NCT06385522
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune SystemNo drug interventionstreatment1not_yet_recruiting
NCT05781386
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumorstreatment1recruiting
NCT04014374
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With MogamulizumabNo drug interventionsNot AvailableNot Availablerecruiting
NCT03932279
Characterization of the Microbiome in Cutaneous T Cell LymphomaNo drug interventionsNot AvailableNot Availablerecruiting
NCT03602157
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCLtreatment1recruiting
NCT03385226
A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)treatment2active_not_recruiting
NCT03340155
Mechanisms of Action of Photo(Chemo)Therapy in Skin DiseasesNo drug interventionsotherNot Availableunknown_status
NCT02576496
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignanciestreatment1completed
NCT02546440
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)treatment2completed
NCT01569724
Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell LymphomaNo drug interventionstreatment4completed
NCT01198665
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomastreatment1 / 2completed
NCT00178841
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCLtreatment2completed
NCT03357224
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)treatment2terminated
NCT00699296
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphomatreatment2terminated
NCT04296786
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Studytreatment2recruiting
NCT00038025
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignanciestreatment2completed
NCT00043420
CPG 7909 in Patients With Cutaneous T-Cell Lymphomatreatment1 / 2completed
NCT00106431
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)treatment2completed
NCT04447027
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignanciestreatment1active_not_recruiting
NCT00554827
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomatreatment1completed
NCT00744991
A Study for Participants With Relapsed Cutaneous T-Cell Lymphomatreatment2completed
NCT05106192
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.supportive_careNot Availablenot_yet_recruiting
NCT02953301
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)treatment2completed
NCT03742804
Study Of Intratumoral G100 In Cutaneous T Cell LymphomaNo drug interventionstreatment2withdrawn
NCT01226472
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001treatment2completed
NCT00306969
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphomatreatment1 / 2completed
NCT00051012
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patientstreatment4completed
NCT00431912
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphomatreatment2completed
NCT02039895
Helical Irradiation of Total Skin (HITS) for Cutaneous LymphomaNo drug interventionstreatmentNot Availableunknown_status
NCT00863395
Recalcitrant Pruritus in Cutaneous T-Cell LymphomaNo drug interventionsdiagnostic1 / 2terminated
NCT03192202
AFM13 in Relapsed/Refractory Cutaneous Lymphomastreatment1 / 2completed
NCT00071084
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.treatment2completed
NCT03617224
Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrometreatment1withdrawn
NCT00476554
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphomatreatment2terminated
NCT02314247
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphomatreatment2terminated
NCT02213861
Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphomatreatment2unknown_status
NCT06485219
A Phase IIa Clinical Study of Puesta Mesylate for Injection in Patients With T-Cell Lymphoma and Cutaneous T-Cell LymphomaNo drug interventionstreatment2recruiting
NCT05569057
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell LymphomaNo drug interventionstreatment1recruiting
NCT02616965
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphomatreatment1active_not_recruiting
NCT00611208
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)treatment2completed
NCT01843998
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)treatment2withdrawn
NCT02580552
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLtreatment1completed
NCT01396070
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Leveltreatment2completed
NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesNo drug interventionstreatment1recruiting
NCT00501735
Forodesine in the Treatment of Cutaneous T-Cell Lymphomatreatment2completed
NCT05156229
A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).No drug interventionstreatment1terminated
NCT05225584
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumorstreatment1recruiting
NCT03240211
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCLtreatment1recruiting
NCT02757248
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCLtreatment1withdrawn
NCT04171791
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)treatment1completed
NCT05879458
Ritlecitinib in CTCLtreatment2recruiting
NCT02556463
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumorstreatment1terminated
NCT04087629
StrataCTX® as a Steroid Sparing DeviceNo drug interventionssupportive_careNot Availablerecruiting
NCT03239392
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCLtreatment1 / 2completed